Dr Hadoux on the Efficacy of Selpercatinib in RET-Mutant Medullary Thyroid Cancer

Commentary
Video

Julien Hadoux, MD, PhD, discusses the efficacy of selpercatinib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer as seen in the phase 3 LIBRETTO-531 trial.

Julien Hadoux, MD, PhD, medical oncologist, attending physician, Gustave Roussy, Villejuif, France, discusses the efficacy of selpercatinib (Retevmo) in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer as seen in the phase 3 LIBRETTO-531 (NCT04211337) trial.

Although this selective and potent RET inhibitor has demonstrated high activity and is approved for the treatment of patients with RET-mutant medullary thyroid cancer, it has not been directly compared with that of other approved multikinase inhibitors. Accordingly, this randomized study directly aimed to determine the optimal first-line regimen for this treatment population by assessing the efficacy of selpercatinib vs physician's choice of cabozantinib (Cabometyx) or vandetanib (Caprelsa).

Patients had a documented history of progressive disease without prior exposure to kinase inhibitors within 14 months of enrollment onto the study. A total of 291 patients were included across 176 cancer centers and the primary end point of the study was progression-free survival (PFS) by blinded independent central review.

Findings from the pre-planned interim analysis, which was conducted after 59 PFS events occurred, demonstrated that the median PFS was not reached with selpercatinib (95% CI: non-evaluable [NE]-NE), Hadoux reports. Conversely, median PFS was 16.8 months (95% CI: 12.2-25.1) with the control after a median follow-up of 12 months. This difference was significant and favored the selpercatinib arm, with a hazard ratio (HR) of 0.280 (95% CI: 0.165-0.475; P < 0.0001), he adds.

The BICR-assessed overall response rate (ORR) was higher with selpercatinib at 69.4% (95% CI: 62.4%-75.8%) compared with 38.8% (95% CI: 29.1%-49.2%) in the control group (odds ratio, 3.7; 95% CI, 2.2-6.3; P < 0.0001), Hadouz continues. At a median follow-up of 15 months, selpercatinib produced a superior overall survival benefit vs the control, with an HR of 0.374 (95% CI: 0.147-0.949; P = 0.0312).

Overall, the study met the interim analysis criteria for efficacy (two-sided P value < 0.0033), and the results support the use of selpercatinib as the standard of care for this patient population in the first-line, he details. Selpercatinib's efficacy and durability of response also highlights the importance of selectively targeting of RET-mutant medullary thyroid cancer, Hadoux concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD